TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01083095

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Sporozoite Challenge Model for Plasmodium vivax in Humans
Description: Eighteen naïve volunteers were exposed to the bite of carrying P. vivax sporozoites. Volunteers were randomly allocated to 1 of 6 groups and exposed to different numbers of mosquito biting, for 10 min. After feeding, dissection of all mosquitoes exposed in the cage was performed, to confirm the presence of a blood meal in their midguts and sporozoites in their salivary glands. If a volunteer did not get the number of infective bites assigned for his/her group, he/she was allowed to be bitten for a new group of mosquitoes until a total of 3±1, 6±1, or 9±1 mosquito bites were achieved.
Study: NCT02780544

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: incubator
Description: staying in incubator during eye examination.
Study: NCT01083095

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Sporozoite Challenge Model for Plasmodium vivax in Humans
Description: Eighteen naïve volunteers were exposed to the bite of carrying P. vivax sporozoites. Volunteers were randomly allocated to 1 of 6 groups and exposed to different numbers of mosquito biting, for 10 min. After feeding, dissection of all mosquitoes exposed in the cage was performed, to confirm the presence of a blood meal in their midguts and sporozoites in their salivary glands. If a volunteer did not get the number of infective bites assigned for his/her group, he/she was allowed to be bitten for a new group of mosquitoes until a total of 3±1, 6±1, or 9±1 mosquito bites were achieved.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Sporozoite Challenge Model for Plasmodium vivax in Humans
Description: Eighteen naïve volunteers were exposed to the bite of carrying P. vivax sporozoites. Volunteers were randomly allocated to 1 of 6 groups and exposed to different numbers of mosquito biting, for 10 min. After feeding, dissection of all mosquitoes exposed in the cage was performed, to confirm the presence of a blood meal in their midguts and sporozoites in their salivary glands. If a volunteer did not get the number of infective bites assigned for his/her group, he/she was allowed to be bitten for a new group of mosquitoes until a total of 3±1, 6±1, or 9±1 mosquito bites were achieved.
Study: NCT03999892

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ACHIEVE
Description: The investigators will test two modules of the adapted video-assisted curriculum format of 45 to 60-minute multipurpose classes, which will include a segment on group weight management (\~20-30 minutes) and group exercise (\~20-30 minutes). Within each module, the group weight management topic varies by week, and within each week the content of the three weight management groups builds gradually and is purposely repeated. Within each module, the group exercise classes will focus on mild to moderate intensity aerobic exercise using an exercise video. In this pilot study, a trained study interventionist will deliver the ACHIEVE-D curriculum.
Study: NCT01976832

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Music with movement
Description: Participants in the intervention group will receive the intervention delivered by their family member according to the validated 8-week music with movement (MWM) intervention protocol.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Social interaction
Description: The control group will receive a protocol for social interaction as the control condition, where caregivers were asked to discuss up to date news with PWeD.~The design of the control condition will be highly similar to the MWM protocol in terms of the frequency and duration of the sessions, the number of people involved, and the total intervention period.
Study: NCT00656630

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acamprosate
Description: Two 333mg capsules, 3 times daily (Total dose, 1998 mg daily), 1 week duration

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naltrexone
Description: 50mg capsule, Once daily, 1 week duration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matched placebo capsule, 1 week duration
Study: NCT00682188

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Counseling Intervention
Description: Six 30-minute individual student-centered counseling sessions based on the 5A approach to assist adolescents in making changes in their diet and level of physical activity delivered by school nurses over 2 months (weekly in month 1, biweekly in month 2)

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Information Intervention
Description: Six individual sessions with the school nurse over 2 months to check weight and behavioral changes and provide a series of six pamphlets on weight and weight management
Study: NCT03858946

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Simple trapeziectomy
Description: A curvilinear incision is made over the base of the 1. metacarpal towards the tendon of the extensor pollicis brevis in the distal part of the anatomical snuffbox. The joint is opened as widely as possible and the trapezium is dissected free in a proximal direction until the articulation with the scaphoid is reached. Then trapezium is removed taking care not to damage tendon of the flexor carpi radialis. The joint capsule is closed and skin sutured in the usual manner. At the completion of the procedure two small shame incision are made (1 cm each) involving only epidermis on the volar aspect of the palm and forearm. Each of them will be closed with one stitch

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Weilby
Description: The first part of the surgical procedure is identical to simple trapeziectomy. In addition, the tendon sheath of the first extensor compartment is divided. After this, a strip consisting of approximately one-third of flexor carpi radialis tendon is dissected using two small incisions on the volar aspect of the wrist and distal forearm. The distally based tendon strip is tunneled to its insertion on the second metacarpal bone. Then the strip of tendon is winded around the abductor pollicis longus tendon and the rest of the tendon at least twice, pulling those tendons together into the space created after excision of the trapezium. The tendons are sutured together with non-absorbable sutures while the skin is sutured in the usual manner
Study: NCT03088254

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Group I (Telmisartan 80 mg, Amlodipine 10 mg, Rosuvastatin 20 mg)
Description: Twinstar(80/10 mg) and Rosuvastatin 20 mg for 8 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Group II (Telmisartan 80 mg, Amodipine 10 mg, Rosuvastatin placebo)
Description: Twinstar(80/10 mg) and Rosuvastatin placebo for 8 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Group III (Telmisartan 80 mg, Amlodipine placebo, Rosuvastatin 20 mg)
Description: Twinstar placebo, Amlodipine 10 mg and Rosuvastatin 20 mg for 8 weeks
Study: NCT01965288

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: comfilcon A
Description: test lens Pair(comfilcon A) or the control lens Pair(lotrafilcon B)
Study: NCT02780544

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sucrose
Description: oral sucrose before eye examination
Study: NCT01965288

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: comfilcon A
Description: test lens Pair(comfilcon A) or the control lens Pair(lotrafilcon B)
Study: NCT02780544

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sucrose
Description: oral sucrose before eye examination
Study: NCT03318016

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide 500 MG
Description: ATO at a fixed dose of 0.15 mg/kg/d IV followed by Cyclophosphamide 500 mg/m2 on day 4 as a single IV dose along with hydration for a maximum of 6 doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide 1000 MG
Description: Enrolled subjects will receive 3 consecutive days of ATO at a fixed dose of 0.15 mg/kg/d IV followed by Cyclophosphamide 1000 mg/m2on day 4 as a single IV dose along with Mesna (in subjects receiving ≥1000mg/m2 Cy) and hydration for a maximum of 6 doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide 2000 MG
Description: Enrolled subjects will receive 3 consecutive days of ATO at a fixed dose of 0.15 mg/kg/d IV followed by Cyclophosphamide 2000 mg/m2on day 4 as a single IV dose along with Mesna (in subjects receiving ≥1000mg/m2 Cy) and hydration for a maximum of 6 doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide 3000 MG
Description: Enrolled subjects will receive 3 consecutive days of ATO at a fixed dose of 0.15 mg/kg/d IV followed by Cyclophosphamide 3000 mg/m2on day 4 as a single IV dose along with Mesna (in subjects receiving ≥1000mg/m2 Cy) and hydration for a maximum of 6 doses
Study: NCT01965288

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: lotrafilcon B
Description: test lens Pair(comfilcon A) or the control lens Pair(lotrafilcon B)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: lotrafilcon B
Description: test lens Pair(comfilcon A) or the control lens Pair(lotrafilcon B)
Study: NCT01243359

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sunitinib malate
Description: Given PO

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: fluorine F 18 fluorothymidine
Description: Undergo FLT PET/CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: positron emission tomography
Description: Undergo FLT PET/CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: computed tomography
Description: Undergo FLT PET/CT
Study: NCT03318016

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide 4000 MG
Description: Enrolled subjects will receive 3 consecutive days of ATO at a fixed dose of 0.15 mg/kg/d IV followed by Cyclophosphamide 4000 mg/m2on day 4 as a single IV dose along with Mesna (in subjects receiving ≥1000mg/m2 Cy) and hydration for a maximum of 6 doses
Study: NCT00855491

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Phaco
Description: AcrySof Single-Piece IOL

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Phaco
Description: AcrySof Single-Piece IOL
Study: NCT02510378

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Short course radiotherapy
Description: Patients with rectal cancer and resectable liver metastases receive 25 Gy in 5 fractions of 5 Gy over 5 days to the pelvis and XELOX consolidating chemotherapy (with or without target therapy) al least 4 cycles after 2 weeks.~After evaluation, patients with resectable rectal cancer and liver metastasis will undergo surgery. Those patients with unresectable lesions will receive chemotherapy.
Study: NCT04056195

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SKI-O-703
Description: The SKI-O-703 capsules will contain 100 mg of drug substance.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SKI-O-703
Description: The SKI-O-703 capsules will contain 100 mg of drug substance.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: Placebo capsules are filled with microcrystalline cellulose.
Study: NCT02816489

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Clarity SL MBT brackets; 3M Unitek, Monrovia, CA, USA
Description: (passive self-ligating ceramic orthodontic brackets with stainless steel archwire slot liner)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Gemini MBT brackets; 3M Unitek, Monrovia, CA, USA
Description: (conventional stainless steel orthodontic brackets ligated with elastomeric ligature)
Study: NCT04557709

Intervention type: OTHER
Intervention: Medical Chart Review
Description: Review of medical charts
Study: NCT04056195

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo oral tablet
Description: Placebo capsules are filled with microcrystalline cellulose.
Study: NCT00592566

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone, desmopressin
Description: 200 mg of dexamethasone IV infusion OD for 3 days or 0.3 microgram/ kg of desmopressin in 50 ml of saline, as a 30- minute infusion
Study: NCT03791775

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Polidocanol foam (Atossisclerol® 3%)
Description: The procedure will be performed in the Sims position or lithotomy position. A modified Blonde-Blanchard technique will be adopted, with the tangential injection of polidocanol foam into the submucosa of the apex of each hemorrhoidal pile, without exceeding three piles, and using a self-lighting open-ended anoscope and a 20-G needle in order to reduce bleeding
Study: NCT01995799

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ferumoxytol enhanced MRI
Description: Ferumoxytol enhanced MRI scan

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ferumoxytol enhanced MRI
Description: Ferumoxytol enhanced MRI scan

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ferumoxytol enhanced MRI
Description: Ferumoxytol enhanced MRI scan
Study: NCT00603746

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GW685698X
Description: GW685698X
Study: NCT01318096

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: raltegravir and tenofovir and lamivudine
Description: raltegravir 400mg BID and tenofovir 300mg qd and lamivudine 300mg gd for 48 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: efavirenz+tenofovir+lamivudine
Description: efavirenz 600mg QN +tenofovir 300mg qd +lamivudine 300mg qd for 48 weeks
Study: NCT00563953

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposomal pegylated doxorubicine
Description: Four cycles of liposomal pegylated doxorubicine at 35 mg/m² IV combined with cyclophosphamide at 600 mg/m² on Day 1 every 4 weeks, and followed by paclitaxel 80 mg/m²/week for 12 weeks before surgery.
Study: NCT01104636

Intervention type: DRUG
Intervention: Varenicline
Description: varenicline tablets prescribed as per local German SmPC for 12 weeks duration
Study: NCT03664752

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IDP-120 Gel
Description: IDP-120 Gel, once-daily application

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: IDP-120 Vehicle Gel
Description: IDP-120 Vehicle Gel, once-daily application
Study: NCT01524627

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Varenicline
Description: Varenicline will be prescribed to non-abstinent smokers at the same doses as have been demonstrated to be clinically effective: 0.5 mg twice a day for 3 days and then 1mg twice daily for the remainder of the treatment course of 8 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be prescribed to non-abstinent smokers at the same doses as have been demonstrated to be clinically effective for Varenicline: 0.5 mg twice a day for 3 days and then 1mg twice daily for the remainder of the treatment course of 8 weeks.
Study: NCT04073381

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Prehabilitation Program
Description: This is a 4 week prehabilitation program which uses both exercise and nutrition. Exercise will be prescribed at least 6 days a week. Three days a week , for 45 mins, participants will be asked to perform body, leg and arm exercises against light resistance while wearing pneumatic blood flow restriction arm and leg bands. minutes. On the alternate days participants will walk approximately 15 minutes while wearing the leg bands that restrict blood flow. Additionally, a nutrition supplement cocktail will be provided and should be taken every day within 1 hour after completing each exercise session. The 4 Week Nutrition (Sports Drink) Supplement Cocktail: will include whey protein (25 g/day), creatine monohydrate (8 g/day), and L-citrulline (5 g/day). The supplement mixture will be provided in daily packages by the investigators (nutrition supplements are not regulated by the FDA)
Study: NCT05252039

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Goals in Focus
Description: Goals in Focus (GiF) is a symptom-specific treatment program that targets motivational negative symptoms in patients with schizophrenia-spectrum disorders.~The aim is to improve setting and pursuit of personal relevant goals.~GiF follows a 24-individual-sessions treatment manual. GiF includes five treatment phases: 1) Preparation, 2) Goal-setting, 3) Goal-pursuit, and 4) Reflection and preparation of autonomous goal-pursuit. The interventions include generating positive goals, behavioral activation, training of anticipatory pleasure, challenging demotivating beliefs, training of problem-solving skills and social skills training.
Study: NCT00275951

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab Plus P-HDFL
Description: Cetuximab 400 mg/m2, IV, day 1 of cycle 1; then weekly IV 250 mg/m2. Cisplatin 24-hour IV infusion 35 mg/m2/day, plus HDFL (5-FU 2,000 mg/m2 and leucovorin 300 mg/m2), day 1 and day 8. HDFL IV, day 15.
Study: NCT03402438

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulacimstat (BAY1142524)
Description: single oral dose of 25 mg immediate-release tablet BAY1142524

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulacimstat (BAY1142524)
Description: single oral dose of 25 mg immediate-release tablet BAY1142524

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulacimstat (BAY1142524)
Description: single oral dose of 25 mg immediate-release tablet BAY1142524

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulacimstat (BAY1142524)
Description: single oral dose of 25 mg immediate-release tablet BAY1142524
Study: NCT01449526

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: B&L Investigational Contact Lens
Description: Lenses will be worn on a daily wear basis for 3 months, new lenses dispensed monthly.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: B&L PureVision Contact Lens
Description: Lenses will be worn on a daily wear basis for 3 months, new lenses dispensed monthly.
Study: NCT01575184

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: caudo-ipsilateral traction of shoulder
Description: After the head rotation (0, 40, 80 degrees) to the contralateral side from the ultrasound measuring site, the slight caudo-ipsilateral traction of shoulder will be applied without changing the degree of the head rotation.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: The ultrasonographic measurements without shoulder traction
Description: After the head rotation (0, 40, 80 degrees) to the contralateral side from the ultrasound measuring site, the no traction of shoulder will be applied.
Study: NCT04278521

Intervention type: DEVICE
Group type: OTHER
Intervention: Transcranial Magnetic Stimulation
Description: Transcranial magnetic stimulation uses a rapidly changing magnetic field to induce current in brain tissue non-invasively. It is common procedure in both clinical and research settings, and it has well established guidelines for safe an ethical use which maximize safety for all subjects.
Study: NCT01500642

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Slit One
Description: slit one sublingual immunotherapy 200 stu

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Slit One
Description: slit one vestibular immunotherapy 200 stu

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Slit One ragweed
Description: slit one 400 stu dose ragweed (sublingual doubled immunotherapy)
Study: NCT03073590

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Intervention factory with hot lunch
Description: A nutritionally enhanced lunch meal program (increased dietary diversity plus inclusion of multi-nutrient fortified rice), provision of once weekly iron/folate supplement to female workers, and a BCC program conducted in the factory setting focused on improving health and nutrition for women and children, with a focus on anemia prevention.The BCC program will be enhanced to include modules on nutrition (balanced diets/dietary diversity, iron/folate rich foods), infant and young child nutrition (IYCN), and an overview module on anemia prevention, hand-washing with soap and dietary diversity at the very beginning of the intervention.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Intervention factory without lunch program
Description: In a selected garment factory that does not have a lunch program, the intervention will consist of the twice weekly provision of iron/folate supplements to female workers, and the enhanced BCC program, as described above.

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Control factory with lunch program
Description: One control factory who provides regular lunch meal and a nutrition and health behavior change communications (BCC) program.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control factory without lunch program
Description: One control factory was selected where only the standard Behavior change communication (BCC) was implemented.
Study: NCT01794091

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eplerenone
Description: Eplerenone 25 mg daily for 6 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo